The Hebrew University team's metamodel brings these models together, drawing from data on how critical molecules—T-cell receptors (TCR), CD45, and Lck—interact and move at the initial points ...

Iomab-ACT is a next-generation CD45 targeted conditioning agent being developed for cell and gene therapies for both malignant and non-malignant hematologic indications. Actimab-A Regulatory and ...

3. Project 2 Radiolabeled Therapy of Lymphoma; A phase I clinical trial of 90Y-labeled anti-CD45 BC8 antibody will be conducted in patients with lymphoma undergoing autologous stem cell ...